From the Guidelines
Valsartan and Benicar (olmesartan) have similar effectiveness as angiotensin II receptor blockers (ARBs) when used at appropriate doses, with valsartan typically prescribed at 80-320 mg daily and Benicar at 20-40 mg daily, as shown in Table 28 of the study by 1. The concept of one being "stronger" than the other is misleading, as their potency is not directly comparable due to differences in bioavailability and half-life. Valsartan and olmesartan work by blocking angiotensin II receptors, which helps to relax blood vessels and lower blood pressure. Some key points to consider when choosing between these medications include:
- Individual response to the medication, which can vary significantly between patients
- Side effect profiles, which are similar and include dizziness, headache, and elevated potassium levels
- Cost and insurance coverage
- Dosing schedule preference
- Tolerance to the medication According to the study by 1, ACE inhibitors and ARBs, including valsartan and olmesartan, are effective in slowing the progression of kidney disease characterized by microalbuminuria in hypertensive patients with type 1 or type 2 diabetes. The goal doses for these medications should be at the higher end of the dose range when possible, as indicated in the study by 1. Ultimately, the choice between valsartan and Benicar should be based on individual factors rather than perceived strength, and patients should consult with their healthcare provider to determine the best course of treatment.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Comparison of Valsartan and Benicar (Olmesartan)
- Valsartan and olmesartan are both angiotensin II receptor blockers (ARBs) used to treat hypertension and heart failure 2, 3, 4.
- A network meta-analysis found that olmesartan had the highest ranking in reducing office systolic and diastolic blood pressure, while valsartan was less effective in lowering blood pressure than other ARBs, including olmesartan 4.
- Another study found that switching from valsartan to candesartan significantly reduced morning and office blood pressures in Japanese patients with morning hypertension 5.
- There is no direct comparison between valsartan and benicar (olmesartan) in the provided studies, but the available data suggest that olmesartan may be more effective in reducing blood pressure than valsartan 3, 4.
Efficacy and Safety of Valsartan and Olmesartan
- Valsartan has been shown to be effective in reducing blood pressure and improving outcomes in patients with hypertension, heart failure, and chronic kidney disease 2.
- Olmesartan has also been shown to be effective in reducing blood pressure and has a favorable safety profile, with a lower incidence of adverse events compared to other ARBs 4, 6.
- However, the addition of olmesartan to combination therapy with ACE inhibitors and β-blockers was associated with increased adverse cardiac events and renal dysfunction in hypertensive patients with chronic heart failure 6.